+

WO2003000709A3 - Sialinsäure-derivate als siglec-inhibitoren - Google Patents

Sialinsäure-derivate als siglec-inhibitoren Download PDF

Info

Publication number
WO2003000709A3
WO2003000709A3 PCT/EP2002/006277 EP0206277W WO03000709A3 WO 2003000709 A3 WO2003000709 A3 WO 2003000709A3 EP 0206277 W EP0206277 W EP 0206277W WO 03000709 A3 WO03000709 A3 WO 03000709A3
Authority
WO
WIPO (PCT)
Prior art keywords
siglec
inhibitors
acid derivatives
siglec inhibitors
sialic acid
Prior art date
Application number
PCT/EP2002/006277
Other languages
English (en)
French (fr)
Other versions
WO2003000709A9 (de
WO2003000709A2 (de
Inventor
Sorge Kelm
Reinhard Brossmer
Original Assignee
Sorge Kelm
Reinhard Brossmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001129332 external-priority patent/DE10129332A1/de
Application filed by Sorge Kelm, Reinhard Brossmer filed Critical Sorge Kelm
Priority to EP02748751A priority Critical patent/EP1397374A2/de
Priority to AU2002319207A priority patent/AU2002319207B2/en
Priority to US10/481,529 priority patent/US7820714B2/en
Priority to KR10-2003-7016631A priority patent/KR20040040408A/ko
Priority to CA2451051A priority patent/CA2451051C/en
Priority to JP2003507112A priority patent/JP2004534085A/ja
Publication of WO2003000709A2 publication Critical patent/WO2003000709A2/de
Publication of WO2003000709A9 publication Critical patent/WO2003000709A9/de
Publication of WO2003000709A3 publication Critical patent/WO2003000709A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/027—Keto-aldonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Die Erfindung betrifft Siglec-Inhibitoren mit erhöhter Affinität für das Rezeptormolekül. Vorzugsweise sind die bereitgestellten Siglec-Inhibitoren selektiv für ein gegebenes Siglec-Molekül. Die Erfindung stellt ferner Verfahren zum Herstellen der Siglec-Inhibitoren und Verfahren zum Erhöhen der Bindungsselektivität für ein gegebenes Siglec-Molekül bereit. Die Erfindung betrifft ferner pharmazeutische Zusammensetzungen, die die Siglec-Inhibitoren enthalten. Weiterhin werden medizinische Indikationen der Siglec-Inhibitoren angegeben.
PCT/EP2002/006277 2001-06-19 2002-06-07 Sialinsäure-derivate als siglec-inhibitoren WO2003000709A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP02748751A EP1397374A2 (de) 2001-06-19 2002-06-07 Siglec-inhibitoren
AU2002319207A AU2002319207B2 (en) 2001-06-19 2002-06-07 Sialic acid derivatives for use as siglec inhibitors
US10/481,529 US7820714B2 (en) 2001-06-19 2002-06-07 Siglec inhibitors
KR10-2003-7016631A KR20040040408A (ko) 2001-06-19 2002-06-07 시글렉 억제제
CA2451051A CA2451051C (en) 2001-06-19 2002-06-07 Siglec inhibitors
JP2003507112A JP2004534085A (ja) 2001-06-19 2002-06-07 シグレック阻害剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2001129332 DE10129332A1 (de) 2001-06-19 2001-06-19 Sialinsäure-Derivate als Siglec-Inhibitoren
DE10129332.1 2001-06-19
DE10216310.3 2002-04-12
DE10216310 2002-04-12

Publications (3)

Publication Number Publication Date
WO2003000709A2 WO2003000709A2 (de) 2003-01-03
WO2003000709A9 WO2003000709A9 (de) 2003-04-10
WO2003000709A3 true WO2003000709A3 (de) 2003-09-25

Family

ID=26009544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006277 WO2003000709A2 (de) 2001-06-19 2002-06-07 Sialinsäure-derivate als siglec-inhibitoren

Country Status (8)

Country Link
US (1) US7820714B2 (de)
EP (1) EP1397374A2 (de)
JP (1) JP2004534085A (de)
KR (1) KR20040040408A (de)
CN (1) CN100491389C (de)
AU (1) AU2002319207B2 (de)
CA (1) CA2451051C (de)
WO (1) WO2003000709A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060058830A (ko) 2004-11-26 2006-06-01 한국표준과학연구원 개별시료 주입구가 없는 다중채널 전기영동장치에 의한분리방법
EP2013624B1 (de) * 2006-03-14 2011-08-03 Universität Basel Verfahren zur identifizierung neuer leitverbindungen für arzneistoffkandidaten
US20070244038A1 (en) * 2006-04-12 2007-10-18 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
EP2098246B1 (de) * 2006-12-26 2017-06-28 Japan Science and Technology Agency Verfahren zum screening nach substanzen, die durch hemmung der cd22-funktion in b-zellen eine immunantwort fördern
DE102007046388A1 (de) * 2007-09-21 2009-09-10 Universität Hamburg Entwicklung eines Bindungsassays und Darstellung neuartiger Inhibitoren des Myelin Assoziierten Glycoproteins
RU2013119983A (ru) * 2010-10-05 2014-11-20 Дайити Санкио Компани, Лимитед Антитело, направленное на связанный с остеокластами белок сиглек-15
EP2610263A1 (de) 2011-12-30 2013-07-03 Brossmer, Reinhard Sialinsäure-Dimere
AU2013279241A1 (en) 2012-06-21 2015-01-22 Reinhard Brossmer Sialic acid derivatives
JP6403062B2 (ja) * 2012-12-21 2018-10-10 国立大学法人徳島大学 組織修復活性組成物及びその利用
WO2014160871A2 (en) * 2013-03-27 2014-10-02 The General Hospital Corporation Methods and agents for treating alzheimer's disease
ES2759503T3 (es) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugados de una glicoproteína o un glicano con una carga útil tóxica
EP2910561A1 (de) 2014-02-25 2015-08-26 Reinhard Brossmer Sialinsäurederivate
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
CN105017340B (zh) * 2015-08-05 2017-11-14 厦门大学 一种抗原连接的唾液酸及其应用
SG11201803567XA (en) * 2015-10-29 2018-05-30 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
EP3481374A1 (de) 2016-07-08 2019-05-15 The Scripps Research Institute Desensibilisierung von mastzellen durch co-präsentation von antigenen mit hochaffinen mastzellen-siglec-liganden
WO2018098342A1 (en) * 2016-11-23 2018-05-31 The Regents Of The University Of California N-acetylated sialic acids and related sialosides
CN107501291B (zh) 2017-10-14 2020-01-21 厦门诺康得生物科技有限公司 一种cd169高亲和力抗肿瘤化合物及其制备方法和应用
CN108047282B (zh) * 2017-12-19 2020-06-09 厦门诺康得生物科技有限公司 一种唾液酸衍生物及其制备方法和应用
CN108676044B (zh) * 2018-05-16 2021-03-30 厦门诺康得生物科技有限公司 一种cd33亲和的唾液酸衍生物及其应用
CN108728412B (zh) * 2018-06-08 2021-11-09 厦门诺康得生物科技有限公司 一种nk细胞表面修改的免疫检查点抑制剂及其应用
CN108743595B (zh) * 2018-06-08 2020-11-27 厦门诺康得生物科技有限公司 一种nk细胞免疫检查点抑制剂及其制备方法
CN111973608B (zh) * 2020-09-17 2023-05-23 准邑科技(厦门)有限公司 一种唾液酸衍生物的用途
CN116003486B (zh) * 2023-03-27 2023-08-01 北京天之泰生物科技有限公司 一种先导化合物、其制备方法、以及其在制备抗流感病毒药物方面的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022301A1 (en) * 1991-06-10 1992-12-23 Alberta Research Council Immunosuppressive and tolerogenic oligosaccharide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022301A1 (en) * 1991-06-10 1992-12-23 Alberta Research Council Immunosuppressive and tolerogenic oligosaccharide derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KELM S ET AL: "FUNCTIONAL GROUPS OF SIALIC ACIDS INVOLVED IN BINDING TO SIGLECS (SIALOADHESINS) DEDUCED FROM INTERACTIONS WITH SYNTHETIC ANALOGUES", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 255, no. 3, 1998, pages 663 - 672, XP000913907, ISSN: 0014-2956 *
M. FERNANDA TRONCOSO ET AL.: "Specifity of the binding site of the sialic acid-binding lectin from ovine placenta, deduced from interactions with Synthetic analogues", GLYCOCONJUGATE JOURNAL, vol. 17, 2000, pages 705 - 711, XP008008959 *
MIRELIS P ET AL: "Photoreactive CMP-sialic acids as substrates for alpha2,6-sialyltransferase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 23, 7 December 1995 (1995-12-07), pages 2809 - 2814, XP004135172, ISSN: 0960-894X *
NORTON A K ET AL: "THE SYNTHESIS OF C-9 MODIFIED DERIVATIVES OF THE ALPHA-METHYL GLYCOSIDE OF KDN METHYL ESTER", JOURNAL OF CARBOHYDRATE CHEMISTRY, NEW YORK, NY, US, vol. 20, no. 2, 2001, pages 227 - 238, XP008008970, ISSN: 0732-8303 *
S. KELM ET AL.: "The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound", J. EXP. MED., vol. 195, 2002, pages 1207 - 1213, XP002227045 *

Also Published As

Publication number Publication date
EP1397374A2 (de) 2004-03-17
US20040176309A1 (en) 2004-09-09
CA2451051C (en) 2012-11-27
WO2003000709A9 (de) 2003-04-10
KR20040040408A (ko) 2004-05-12
CN100491389C (zh) 2009-05-27
CA2451051A1 (en) 2003-01-03
US7820714B2 (en) 2010-10-26
WO2003000709A2 (de) 2003-01-03
JP2004534085A (ja) 2004-11-11
AU2002319207B2 (en) 2007-03-01
CN1656113A (zh) 2005-08-17

Similar Documents

Publication Publication Date Title
WO2003000709A3 (de) Sialinsäure-derivate als siglec-inhibitoren
WO2003027076A3 (en) 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
WO2005033099A3 (en) Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
EP2039699A3 (de) Extraktionsverfahren zur Reinigung von Sucralose
TW200505837A (en) Novel compounds
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
TW200519075A (en) Novel compounds
WO2004009549A3 (en) Piperidines useful for the treatment of central nervous system disorders
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
WO2006037024A3 (en) Salts of decitabine
WO2004096285A3 (en) Anti-infective phosphonate conjugates
WO2002008186A3 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
IL159960A (en) Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
WO2003024928A3 (en) Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
WO2006034154A3 (en) Salts of 5-azacytidine
HUP0401101A3 (en) Topical leave-on compositions containing selected pantothenic acid derivatives
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
AU2002319207A1 (en) Sialic acid derivatives for use as siglec inhibitors
TW200630336A (en) Novel compounds
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
WO2004113297A3 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2004106322A3 (en) Polymorphs of aripiprazole
WO2007075838A3 (en) Pure and stable tiotropium bromide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1-3, 5-19, DESCRIPTION, REPLACED BY NEW PAGES 1-3, 5-19; PAGES 24 AND 25, CLAIMS, REPLACED BY NEW PAGES 24 AND 25; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002748751

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2451051

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 028121708

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003507112

Country of ref document: JP

Ref document number: 1020037016631

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002319207

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10481529

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002748751

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002319207

Country of ref document: AU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载